Read + Share
Lan B, Shi Y, Shao X, Wu F, et al. Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a
randomised, phase 3 trial. Lancet 2026 Oct 26:S0140-6736(26)02096-9. doi: 10.1016/S0140-6736(26)02096.
PMID: 42933459
|
 |
|
Lan B, Shi Y, Shao X, Wu F, et al. Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a
randomised, phase 3 trial. Lancet 2026 Oct 26:S0140-6736(26)02096-9. doi: 10.1016/S0140-6736(26)02096.
PMID: 42933459
|
|
|
|